Skip to main content

InfuSystem Holdings Inc

For the period ended Jun 30, 2024. Filed Aug 9, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 9, 2024

INFU$15.28+4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

-Unaudited Condensed Consolidated Statements of Cash Flows for the

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30,
(in thousands)20242023
OPERATING ACTIVITIES
Net (loss) income$(395)$111
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Provision for doubtful accounts(194)47
Depreciation5,4385,801
Loss on disposal of and reserve adjustments for medical equipment316828
Gain on sale of medical equipment(1,036)(1,402)
Amortization of intangible assets495495
Amortization of deferred debt issuance costs3978
Stock-based compensation2,0551,736
Deferred income taxes405(106)
Changes in assets - (increase)/decrease:
Accounts receivable(1,203)(506)
Inventories(437)(885)
Other current assets(446)(994)
Other assets914(1,719)
Changes in liabilities - (decrease)/increase:
Accounts payable and other liabilities(3,265)(1,183)
NET CASH PROVIDED BY OPERATING ACTIVITIES2,6862,301
INVESTING ACTIVITIES
Purchase of medical equipment(8,796)(6,994)
Purchase of property and equipment(519)(494)
Proceeds from sale of medical equipment, property and equipment2,2012,098
NET CASH USED IN INVESTING ACTIVITIES(7,114)(5,390)
FINANCING ACTIVITIES
Principal payments on long-term debt(26,744)(29,451)
Cash proceeds from long-term debt31,76932,585
Debt issuance costs—(229)
Common stock repurchased as part of share repurchase program(283)(153)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans(624)(523)
Cash proceeds from exercise of options and ESPP225829
NET CASH PROVIDED BY FINANCING ACTIVITIES4,3433,058
Net change in cash and cash equivalents(85)(31)
Cash and cash equivalents, beginning of period231165
Cash and cash equivalents, end of period$146$134
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.